Table 2. Univariate overall survival analysis.
| Variables | No. | Deaths | HR (95% CI) | p | |
|---|---|---|---|---|---|
| Entire cohort | 224 | 60 | - | - | |
| Age (by 5-year increase) | - | - | 1.19 (1.05–1.34) | 0.005 | |
| CCI (1-unit increase) | - | - | 1.32 (1.13–1.55) | <0.001 | |
| BRCA 1 or 2 mutation | 0.067* | ||||
| Negative | 128 | 30 | 1 | ||
| Positive | 35 | 4 | 0.39 (0.14–1.11) | ||
| Stage | 0.066* | ||||
| III | 66 | 12 | 1 | ||
| IV | 158 | 48 | 1.8 (0.95–3.39) | ||
| KPS at cycle 1 (1-unit increase)† | - | - | 0.96 (0.93–0.98) | <0.001 | |
| Albumin at cycle 1 (1-unit increase)† | - | - | 0.29 (0.18–0.47) | <0.001 | |
| NACT regimen† | 0.207 | ||||
| Weekly paclitaxel/carboplatin | 155 | 40 | 1 | ||
| Other | 69 | 20 | 1.42 (0.82–2.43) | ||
| Dose reduction† | 0.006 | ||||
| No | 140 | 32 | 1 | ||
| Yes | 84 | 28 | 2.03 (1.22–3.38) | ||
| Surgery (IDS)† | <0.001 | ||||
| Yes | 162 | 28 | 1 | ||
| No | 62 | 32 | 3.99 (2.31–6.89) | ||
CCI, Charlson comorbidity index; CI, confidence interval; HR, hazard ratio; IDS, interval debulking surgery; KPS, Karnofsky performance status; NACT, neoadjuvant chemotherapy.
*Obtained using the log-rank test; all the other p-values were obtained using the Cox proportional hazards model; ¢ÓThese variables (KPS, albumin, NACT regimen, dose reduction, and IDS) were modeled through time-dependent methodology.